Asian stocks mixed amid unease about vaccine development
Asian stock markets are mixed as questions about the effectiveness of one possible coronavirus vaccine weigh on investor optimism
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Asian stock markets were mixed Friday as questions about the effectiveness of one possible coronavirus vaccine weighed on investor optimism.
Benchmarks in Shanghai, Hong Kong and Sydney retreated while Tokyo and Seoul gained.
Investors have been encouraged by reports of progress toward a possible vaccine. But they were uneasy after researchers questioned data that showed a candidate from the University of Oxford and AstraZeneca was 70% effective.
“Market participants showed increasing signs of nervousness as data errors were revealed,” said Mizuho Bank in a report.
The Shanghai Composite Index lost less than 0.1% to 3,368.12 and the Hang Seng in Hong Kong shed 0.2% to 26,776.83. The Nikkei 225 in Tokyo rose 0.3% to 26,626.81.
The Kospi in Seoul added 0.1% to 2,630.07 while Sydney's S&P-ASX 200 shed 0.5% to 6,603.70.
India's Sensex opened down less than 0.1% at 44,241.06. New Zealand, Bangkok and Jakarta gained while Singapore retreated.
U.S. markets were closed Thursday for a holiday.
Investors are looking forward to a possible vaccine to control the pandemic that plunged the global economy into its deepest slump since the 1930s, though forecasters warn the stock market rebound might be too early to be sustained.
Those hopes were dented this week when researchers questioned how Oxford and AstraZeneca calculated the effectiveness of their vaccine. That alliance is among researchers who have reported the most progress toward a possible vaccine. The AstraZeneca CEO told Bloomberg News the company might conduct another trial.
Investors also are dismayed that U.S. states and European governments are reimposing controls on business and travel as infection rates surge.
The disease has killed more than 1.4 million people worldwide and there are 61 million confirmed cases, according to data gathered by Johns Hopkins University.
Markets are uneasy about U.S. data showing consumer spending weakening and job losses rising.
Supplemental unemployment benefits that supported consumer spending, the engine of the U.S. economy, have expired. Congress is deadlocked on a possible new aid plan.
In energy markets, benchmark U.S. crude lost 75 cents to $44.96 per barrel in electronic trading on the New York Mercantile Exchange. Brent crude, used to price international oils, lost 2 cents to $47.77 per barrel in London.
The dollar fell to 103.97 yen from Thursday’s 104.25 yen. The euro rose to $1.1923 from $1.1906.